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Abstract 
A simple, isocratic HPLC method was newly developed for quantitating intracellular 
fludarabine triphosphate (F-ara-ATP).  Samples (500 µl) were injected onto an 
anion-exchange column and eluted isocratically with phosphate-acetonitrile buffer (flow 
rate: 0.7 ml/min) at an ambient temperature.  F-ara-ATP was quantitated according to its 
peak area at the absorbance of 261 nm.  The standard curve was linear with minimal 
within-day and inter-day variability.  The low and high quantification limits were 50 pmol 
and 20 nmol, respectively.  The method was capable of measuring F-ara-ATP 
generated in cultured leukemic cells in vitro.  Thus, our method will be useful because 
of its sensitivity and simplicity as well as applicability to biological materials. 
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1, Introduction 
 
Fludarabine, (9-β-D-arabinofuranosyl-2-fluoroadenine-5’-monophosphate, 
F-ara-AMP) is a monophosphate form of a deaminase-resistant fluorinated analogue of 
arabinosyladenine [1].  The drug is currently used in the treatment of indolent B-cell 
malignancies such as follicular lymphoma and chronic lymphocytic leukemia [2].  It is 
effective both as an initial therapy and for diseases that have become refractory to other 
drugs [2-4].  Fludarabine is also promising in combination with cytarabine for treating 
acute myelogenous leukemia [5].   
Upon administration, fludarabine is rapidly dephosphorylated to its active 
compound, 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), in the plasma.  After 
being taken up into leukemic cells, F-ara-A is again phosphorylated to fludarabine 
triphosphate (9-β-D-arabinofuranosyl-2-fluoroadenine-5’-triphosphate, F-ara-ATP), the 
intracellular active metabolite of fludarabine [1].  F-ara-ATP competes with dATP as a 
substrate for DNA polymerases and is incorporated into DNA [1, 6, 7].  The incorporation 
of the drug into DNA results in the inhibition of DNA synthesis, which is strongly associated 
with fludarabine-mediated cytotoxicity [1, 6, 7].  Since F-ara-A incorporation into DNA is 
also proportional to the intracellular F-ara-ATP concentration [1], F-ara-ATP is therefore the 
crucial metabolite of fludarabine as the mechanism of action.  F-ara-ATP is also 
important for modulation of cytarabine therapy and inhibition of DNA repair [1, 6-9]. 
In clinic, no correlation has been found between the therapeutic outcome and 
F-ara-ATP in treating chronic lymphocytic leukemia [10].  However, as demonstrated in 
the case of cytarabine, the parameter for predicting the clinical efficacy of a nucleoside 
analogue is not the plasma drug concentration but its triphosphate form in leukemic cells 
[11, 12].  Therefore, taken together with the understanding of the mechanism of action, 
the pharmacokinetic evaluation of F-ara-ATP may provide crucial information on 
scheduling and dosing fludarabine.   
The most widely used assay method was a gradient elution ion-exchange HPLC 
developed by Gandhi and Plunkett et al. [10, 13, 14].  This was sensitive and applicable 
to measuring F-ara-ATP in leukemic cells from patients receiving fludarabine.  In 
general, however, a gradient mode requires a complicated computer-based system to 
control different kinds of elution buffers, which might limit the use of the method only in 
hospitals highly equipped with laboratory sections.  Moreover, a gradient elution 
sometimes shows a base-line drift, thereby leading to unexpected errors in measuring 
peak heights or areas of the target compound in crude, biological materials. 
In the present study, we developed an isocratic HPLC method for measuring 
F-ara-ATP in leukemic cells.  In contrast to the previous method, the isocratic mode is 
simple and inexpensive as it can be run using a single, mechanical pump.  We have 
also demonstrated that our method was accurate, sensitive, and applicable to measuring 
biological samples. 
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2, Experimental 
 
2.1. Chemicals 
 
Na2HPO4, acetonitrile (HPLC grade), phosphoric acid (85%), and perchloric acid 
(60%) were purchased from Nakalai (Kyoto, Japan).  F-ara-A, ATP, CTP, UTP, GTP, and 
cytarabine were purchased from Sigma Chemical Co. (St. Louis, MO, USA).  F-ara-ATP 
(5 mg) was accurately measured and provided by Nihon Schering K.K. (Osaka, Japan).  
Water was home-purified by the combination of reversed osmosis and ion exchange on 
a multi-laboratory basis.  All other chemicals were of analytical grade. 
 
2.2. Preparation of standard F-ara-ATP in aqueous solution 
 
An accurately measured 5 mg of F-ara-ATP was dissolved in water to make a 
stock solution (final concentration 10 mM).  Serially diluted standards were prepared 
from this solution for drawing a standard curve.  They were stored at –80°C until 
analyzed. 
 
2.3. HPLC apparatus and chromatographic conditions 
 
 The HPLC system consisted of a pump CCPM-II (TOSOH Corp., Tokyo, Japan), 
an autosampler AS-8020 (TOSOH Corp., Tokyo, Japan), an in-line degasser SD-8022 
(TOSOH Corp., Tokyo, Japan), and a variable-wavelength detector UV-8020 (TOSOH 
Corp., Tokyo, Japan).  The chromatography was controlled and analyzed using a 
personal computer equipped with the software LC-8020 (TOSOH Corp., Tokyo, Japan).   
 Samples were injected onto an anion-exchange column, TSK gel DEAE-2 SW 
(length x inside diameter 250 x 4.6 mm, particle size 5 µl, TOSOH Corp., Tokyo, Japan).  
The elution was performed isocratically with 0.06 M Na2HPO4 (pH 6.9) -20% acetonitrile 
at a constant flow rate of 0.7 ml/min and at ambient temperature.  F-ara-ATP was 
monitored at 261 nm, the wavelength of the maximum UV absorption of the compound.   
 
2.4. Standard curve and validation 
 
 To validate the method, aqueous solutions of standard F-ara-ATP at 10 different 
concentrations were made from the stock solution by serial dilution (2.2.).  A 500-µl 
aliquot from each diluted standard was injected onto the HPLC to give a final amount of 
F-ara-ATP ranging between 20 pmol and 20 nmol (20 pmol, 50 pmol, 100 pmol, 200 
pmol, 500 pmol, 1 nmol, 2 nmol, 5 nmol, 10 nmol, and 20 nmol).  Measurements of 
these standard solutions in triplicate were performed on three separate days to 
determine the within-day and the inter-day variation.  Data were combined and plotted 
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to determine the linearity between the amounts of F-ara-ATP and the corresponding 
peak areas.  The standard curve was fitted by the weighed least-squares linear 
regression analysis method using the equation, y = ax + b, where a represented the 
slope and b represented the intercept of the standard curve at x = 0.  
 
2.5. Determination of unknown samples 
 
 F-ara-ATP of unknown samples was identified by its retention time by 
comparison with that of the standard F-ara-ATP solution.  The amount of F-ara-ATP 
was calculated by extrapolating the peak area count into the equation of the standard 
curve. 
 
2.6. Cell culture and treatment 
 
 To validate applicability of the method to biological materials, the human 
leukemia HL60 cells were cultured in RPMI1640 (Sigma Chemical Co., St. Louis, MO, 
USA) supplemented with 10% heat-inactivated fetal bovine serum (Sigma Chemical Co., 
St. Louis, MO, USA) in 5% CO2 humidified atmosphere at 37°C.  The cells in a 
logarithmic growth phase (1 x 106 /ml, 20 ml) were incubated with F-ara-A, an active 
compound of fludarabine, at various concentrations for the indicated time periods at 
37°C.  The cells treated or untreated were then washed twice into fresh media.  The 
cell pellet was collected by centrifugation (400x g, 10 min, 4°C) in a micro-test tube, and 
200 µl of 0.3 M cold perchloric acid was added to the pellet.  The mixture was vortexed 
for 10 s, and allowed to stand for 15 min at 4°C.  The acidic supernatant was isolated 
by centrifugation of the sample (15,600x g, 20 s, 4°C), and then mixed with 100 µl of 0.5 
N potassium hydroxide for neutralization.  After another centrifugation (15,600x g, 20 s, 
4°C), the neutralized supernatant was obtained as an acid soluble fraction (ASF), a 
nucleotide pool [12, 15].  The sample loop for the HPLC had a 500-µl space, and the 
dead volume for the aspiration of the sample by the autosampler was 170 µl.  By 
adding 500 µl and 170 µl and some room, the volume of each ASF sample was adjusted 
to 700 µl by the addition of water, and the 500-µl aliquot was applied to the 
chromatographic analysis.  The intracellular concentration of F-ara-ATP was expressed 
as pmol/1 x 107 cells.  The samples were stored at -80°C when they were not used 
immediately.  
 
2.7. Preparation of standard F-ara-ATP mixed with ASF 
 
To further confirm the utility to biological samples, another set of F-ara-ATP 
standards was made using an ASF.  Known amounts of standard F-ara-ATP were 
dissolved an ASF extracted from untreated HL 60 cells, and the sample volume was 
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adjusted to 700 µl by the addition of water.  The 500-µl aliquots were applied to the 
HPLC to give final amounts of F-ara-ATP that were equivalent to those made in water.  
Then, the variation was assessed in the measurement of F-ara-ATP in the ASF.  The 
solutions were stored at -80°C until analyzed. 
 
2.8. Calculations and statistical analyses  
 
 The standard curve was obtained by the weighed least-squares linear 
regression analysis method using GraphPad Prism software (GraphPad Software, Inc., 
San Diego, CA, USA).  The values of coefficient of variation and standard deviation for 
F-ara-ATP measurements were obtained using Microsoft Excel software (Microsoft 
Corporation, Redmond, WA, USA). 
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3. Results and discussion  
 
3.1. Standard curve and Validation 
 
To determine the standard curve, 10 concentration levels of standard F-ara-ATP 
in aqueous solutions (2.2) in triplicate were applied to the present HPLC scheme on 
three separate days.  A linear relation was obtained between the amounts of F-ara-ATP 
(50 – 20,000 pmol) and the corresponding peak areas using all the data sets (r2 = 0.97, p 
< 0.0001).  The parameters for the curve were; intercept = -0.09 ± 0.05; slope = 0.59 ± 
0.01.  For validation, the within-day and the inter-day variability were determined at 
different amounts of F-ara-ATP (Table 1).  The variations were minimal, as all the values 
of % coefficients of variation were less than 10%.  The low and high limits of 
quantification were 50 pmol and 20,000 pmol (20 nmol), respectively.  The limit was 
defined as the lowest or the highest concentration that gave the % coefficient of variation 
< 10%.  The low limit was as sensitive as the previous HPLC method (25 pmol) [10, 13, 
14].  Thus, these results suggested that the present HPLC assay was accurate and 
sensitive for quantitating F-ara-ATP 
 
3.2. Separation of F-ara-ATP in biological samples 
 
To assess the separation of F-ara-ATP, the mixture of standard nucleotides (CTP, 
UTP, ATP, GTP, and F-ara-ATP) was injected onto the HPLC.  The peak of F-ara-ATP 
was clearly isolated from the other nucleotides (Fig. 1A).  The retention time of the 
F-ara-ATP peak was 90 min.  The retention times of standard deoxyribonucleotides 
(dATP, dCTP, dTTP, dGTP) were similar to those of the corresponding ribonucleotides 
(data not shown).   
 To evaluate if the present HPLC condition was applicable to the measurement of 
F-ara-ATP in biological samples, nucleotide pools extracted from leukemic cells were 
tested.  Fig. 1B represented a blank chromatogram of an ASF extracted from untreated 
human leukemia HL 60 cells.  Endogenous nucleoside triphosphates (CTP, UTP, ATP, 
and GTP) were clearly separated in the same way (Fig. 1B), as had been demonstrated 
using standard markers (Fig. 1A).  The chromatogram did not show any peaks between 
ATP and GTP, which might otherwise have interfered with the peak of F-ara-ATP.  When 
the ASF was co-eluted with standard F-ara-ATP, the peak of F-ara-ATP was clearly 
isolated from the other endogenous peaks of the leukemic nucleotides (Fig. 1C), 
suggesting the applicability of the method to biological samples.   
To further confirm the clinical utility, the present method was applied to the 
measurement of F-ara-ATP generated in leukemic cells in vitro.  An ASF was extracted 
from HL 60 cells after treatment with F-ara-A, and then injected onto the HPLC.  Even 
at the minimal concentration of the drug at the shortest incubation time period, the 
 - 7 - 
production of F-ara-ATP in leukemic cells was clearly demonstrated in the chromatogram 
(Fig. 1D).  Thus, these results suggested that the appropriate F-ara-ATP separation was 
obtained in the biological materials under the present HPLC condition. 
 
3.3. Validation of the F-ara-ATP measurement in biological samples 
 
To validate the measurement in biological samples, the method was applied to 
measuring standard F-ara-ATP in an ASF.  Various amounts of standard F-ara-ATP 
dissolved in the ASF of untreated HL 60 cells (2.7.) were injected onto the HPLC to give 
the final F-ara-ATP contents equivalent to those made in water.  Measurements of these 
F-ara-ATP-ASF solutions in triplicate were performed on three separate days to see the 
variability.  The within-day and inter-day variability for F-ara-ATP quantitation was 
minimal, which were indicated as the % coefficient of variation less than 10% (Table 2).   
The corresponding peak areas were compared between the F-ara-ATP-ASF 
solution and the F-ara-ATP-water solution.  Various amounts of standard F-ara-ATP in 
the ASF or in aqueous solution were applied to the present HPLC method.  Upon 
injection, both solutions gave final F-ara-ATP contents of 50 pmol, 200 pmol, 1 nmol, and 
5 nmol.  The peak area counts were similar to each other in both solutions, and a close 
correlation was found (r2 = 0.99, p <0.0001, slope = 0.95 ± 0.006, Y-intercept = 0, 
X-intercept = 0).  The result suggested that F-ara-ATP was quite stable in the ASF and 
that the measurement of F-ara ATP was not disturbed by the endogenous peaks arising 
from the ASF.  Therefore, the present HPLC method would be applicable to the 
quantification of F-ara-ATP in biological samples.  
 
3.4. F-ara-ATP generation in leukemic cells in vitro. 
 
 Using the present HPLC method, the production of F-ara-ATP in leukemic cells 
was quantitated.  When HL 60 cells were incubated with different concentrations for the 
indicated time periods, the production of intracellular F-ara-ATP became greater in time- 
and concentration-dependent manners (Figs. 2A&B).  The F-ara-ATP concentrations in 
HL 60 cells measured here might be within the range of the expected F-ara-ATP 
concentrations (approximately 6-52 µM, which corresponds to 60-520 pmol/1 x 107 cells) 
in primary leukemic cells from patients receiving fludarabine (25-30 mg/m2/day) [10, 16].  
Thus, the present method was capable of measuring F-ara-ATP generated in the 
leukemic cells in vitro, which strongly suggested its clinical applicability. 
 
3.5. Separation of cytarabine triphosphate from F-ara-ATP. 
 
 One of the strategies to overcome the resistance of leukemic cells is the 
combination use of fludarabine with cytarabine.  When HL60 cells were treated with 
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F-ara-A combined with ara-C, the present HPLC analysis was capable of separating 
cytarabine triphosphate (retention time 64 min) from F-ara-ATP in the nucleotide pool 
(Fig. 3).  The results suggested the possibility of simultaneous measurement of the 
corresponding triphosphates of these two compounds in the same run. 
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4. Conclusions  
 
Fludarabine is currently effective not only for indolent hematological 
malignancies but also for acute leukemia.  The pharmacokinetic evaluation of 
F-ara-ATP may provide crucial information on scheduling and dosing fludarabine [17].  
The quantitation method should be simple with the use of less expensive apparatus so 
that clinicians might utilize the pharmacokinetic data for treating patients on a daily basis 
in hospitals.  The whole procedure of the present method was similar to that of the 
previous methods, since this approach might be the best for monitoring phosphate 
metabolites of nucleoside analogues in leukemic cells.  In addition, the isocratic HPLC 
method described here can be controlled not only using a computerized system but also 
using a conventional, mechanical single pump.  Moreover, an isocratic elution may 
allow an accurate measurement of small amounts of F-ara-ATP in crude biological 
extracts because it does not induce a base-line drift.  Thus, the present method will be 
of great advantage because of its sensitivity and simplicity as well as its clinical 
applicability. 
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Legends 
 
Fig. 1. 
HPLC profiles of nucleotides.  A: Standard nucleotides (ATP, CTP, UTP, GTP, and 
F-ara-ATP) dissolved in water were applied to the present HPLC scheme.  B: An acid 
soluble fraction was extracted from untreated human leukemic HL 60 cells (2 x 107 cells), 
and the volume of the extract was adjusted to 700 µl by the addition of water.  A 500-µl 
aliquot was then applied to the HPLC.  C: The above acid soluble fraction was co-eluted 
with standard F-ara-ATP in the same HPLC run.  D: An acid soluble fraction was 
extracted from HL 60 cells after 1-h incubation with 1 µM F-ara-A (the minimal dose and 
incubation time period detectable).  The volume of the extract was adjusted to 700 µl by 
the addition of water, from which a 500-µl aliquot was applied to the HPLC.  
 
Fig. 2. 
Dose- and time-dependent increase in F-ara-ATP production in leukemic cells.  Human 
leukemia HL 60 cells (1 x 106 cells/ml, 20 ml) were incubated with 1 µM (o) or 10 µM (•) 
F-ara-A for indicated time periods (0, 1, 2, 4, 6 h) (A).  Alternatively, the cells were 
incubated for 2 h (o) or 4 h (•) with the indicated concentrations (0, 0.5, 1, 5, 10, 20 µM) 
of F-ara-A (B).  After washing the cells into fresh media, acid soluble fractions were 
extracted from the samples, and the volume of the extracts was adjusted to 700 µl by 
the addition of water.  A 500-µl aliquot from each sample was then applied to the HPLC.  
The amount of F-ara-ATP was calculated by extrapolating the peak area count into the 
equation of the standard curve. 
 
Fig. 3. 
Separation of cytarabine triphosphate from F-ara-ATP.  HL 60 cells (1 x 106 cells/ml, 20 
ml) were incubated with (B) or without (A) 10 µM F-ara-A for 2 h, followed by washing, 
resuspension in fresh media, and a subsequent incubation with 10 µM cytarabine for 3 h.  
After washing the cells into fresh media, acid soluble fractions were extracted from the 
samples, and the volume of the extracts was adjusted to 700 µl by the addition of water.  
A 500-µl aliquot from each sample was then applied to the HPLC.  a; ATP, g: GTP, c; 
CTP, u; UTP, ara-CTP; cytarabine triphosphate. 
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